

Abstract of the Disclosure

The present invention is directed to methods and devices for delivering an active
5 agent formulation to the lung of a human patient. The active agent formulation may be
in dry powder form, it may be nebulized, or it may be in admixture with a propellant.
The active agent formulation is delivered to a patient at an inspiratory flow rate of less
than 17 liters per minute. The bioavailability of the active agent was found to increase
at these flow rates when compared to inspiratory flow rates of 17 liters per minute or
10 more.